ClinicalTrials.gg
CompletedNCT02955602Updated Jul 14, 2022Results posted

Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)

A Phase 2 interventional study of MBX-8025 2 mg Capsule and MBX-8025 5 mg Capsule in Primary Biliary Cirrhosis, sponsored by Gilead Sciences. Completed at 38 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-14.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.

Enrollment
6th of 10
119 · median 126
Started
2016
with 1 other
Phase 2
4 of 10
1 open now
Registered
3rd of 10
by date

Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 3rd registered.

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

Browse Liver Cirrhosis, Biliary studies →

Open to participants now

2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, or all of them as a file.
02

Study summary

An 8-week, dose ranging, open label, randomized, Phase 2 study with a 44-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)

Read the detailed description

Primary:

To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 8 weeks of treatment

Secondary:

To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 12 and 26 weeks of treatment

To evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of treatment

To evaluate the pharmacokinetics (PK) of MBX-8025

Exploratory:

To evaluate the effect of MBX-8025 on bile acids, additional markers of inflammation and renal function

MBX-8025 doses of 1 mg and 15 mg may be evaluated if dose adjustment occurs

03

Conditions studied

  • Primary Biliary Cirrhosis

Keywords

  • PBC
  • Primary Biliary Cholangitis (PBC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written (signed and dated) and any authorizations required by local law
  2. 18 to 75 years old (inclusive)
  3. Male or female with a diagnosis of PBC, by at least two of the following criteria:

    • History of AP above for at least six months
    • Positive AMA titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies
    • Documented liver result consistent with PBC
  4. On a stable and recommended dose of UDCA for the past twelve months or intolerant to UDCA
  5. AP ≥ 1.67 × ULN
  6. Females of must use at least one barrier and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose

Exclusion criteria

Exclusion Criteria:

  1. A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer on active treatment)
  2. or ALT > 3 ×
  3. Total > 2.0 mg/dL
  4. Total bilirubin > ULN AND albumin \< LLN with the exception to subjects with Gilbert's Syndrome. Subjects with Gilbert's syndrome are excluded if Direct Bilirubin > ULN.
  5. Auto-immune hepatitis
  6. Primary sclerosing cholangitis
  7. Known history of alpha-1-Antitrypsin deficiency
  8. Known history of chronic viral hepatitis
  9. Creatine kinase above ULN
  10. Serum creatinine above ULN
  11. For females, pregnancy or breast-feeding
  12. Use of colchicine, methotrexate, azathioprine, or systemic in the two months preceding screening
  13. Current use of fibrates or simvastatin
  14. Current use of obeticholic acid
  15. Use of an experimental or unapproved treatment for PBC
  16. Use of experimental or unapproved
  17. Adverse event leading to MBX-8025 discontinuation from CymaBay's phase 2 PBC study (CB8025-21528)
  18. Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the Investigator
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    MBX-8025 (2 mg)

    MBX-8025 2 mg capsule once daily

    Drug: MBX-8025 2 mg Capsule

  • Experimental
    MBX-8025 (5 mg)

    MBX-8025 5 mg capsule once daily

    Drug: MBX-8025 5 mg Capsule

  • Experimental
    MBX-8025 (10 mg)

    MBX-8025 10 mg capsule once daily

    Drug: MBX-8025 10 mg Capsule

Interventions

  • Initial 8-week treatment: • MBX-8025 2 mg Extension: The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed. Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.

    Also known as: MBX-8025, seladelpar

  • Initial 8-week treatment: • MBX-8025 5 mg Extension: Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.

    Also known as: MBX-8025, seladelpar

  • Initial 8-week treatment: • MBX-8025 10 mg Extension: Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons.

    Also known as: MBX-8025, seladelpar

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8

    Relative change from baseline in serum ALP levels at Week 8 (endpoint). The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. n, denotes number of subjects evaluable for the respective timepoints

    Time frame: 8 weeks

Secondary outcomes

  1. Absolute Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 12 and Week 52

    Absolute change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  2. Change in Aspartate Aminotransferase (AST) From Baseline to 12 Weeks and 52 Weeks

    Change from baseline in AST levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  3. Change in Alanine Aminotransferase (ALT) From Baseline to 12 Weeks and 52 Weeks

    Change from baseline in ALT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  4. Change in Gamma-glutamyl Transferase (GGT) From Baseline to 12 Weeks and 52 Weeks

    Change from baseline in GGT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  5. Change in Bilirubin - Total Bilirubin (TB) From Baseline to 12 Weeks and 52 Weeks

    Change from baseline in TB levels at endpoint is being reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  6. Percentage of Participants Meet Composite Endpoint Criteria of ALP and Total Bilirubin

    Participant meets composite endpoint is defined by participant meets all of the following criteria: * ALP \< 1.67 × upper limit of normal (ULN) * Total Bilirubin within normal limit * \> 15% decrease in ALP Endpoint of Alkaline Phosphatase and Total Bilirubin by Visit (mITT Population)

    Time frame: 12 Weeks and 52 Weeks

  7. Percentage of Participants Meet Published PBC Response Criteria - Paris I

    Percentage of participants with response based on Paris I risk score was defined as ALP less than or equal to (≤) 3x ULN and aspartate aminotransferase (AST) less than or equal to (≤) 2 x ULN and Total Bilirubin ≤ 1 mg/dL. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  8. Percentage of Participants Meet Published PBC Response Criteria - Paris II

    Percentage of participants with response based on Paris II risk score was defined as ALP≤1.5xULN and AST≤1.5xULN and Total Bilirubin ≤ 1 mg/dL. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  9. Percentage of Participants Meet Published PBC Response Criteria - Toronto I

    Percentage of participants with response based on Toronto I risk score defined as ALP ≤ 1.67 x ULN. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  10. UK-PBC Risk Score Value

    The UK-PBC Risk Score at endpoint is defined by the mean percentage risk that a PBC patient treated with ursodeoxycholic acid (UDCA) would develop liver failure requiring liver transplantation in 5, 10 and 15 years from diagnosis. The higher the score might indicate higher risk to death or live transplantation. Formula used for UK-PBC risk score = 1- 0.982 \^EXP(0.0287854\*(ALP12 x ULN-1.722136304) - 0.0422873\*(((TA12 xULN/10)\^-1) - 8.675729006) + 1.4199 \* (LN(BIL12 x ULN/10)+2.709607778)-1.960303\*(Albumin x LLN-1.17673001)-0.4161954\*(Platelet x LLN-1.873564875)). Where, Baseline survivor function = 0.982, 0.941, and 0.893 for 5 years, 10 years and 15 years respectively. ALP12, TA12 and BIL12 refers to the ALP, transaminases (ALT, AST), and total bilirubin assessments, respectively. The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  11. Change From Baseline in Pruritus Visual Analog Score (VAS) at Week 12 and Week 52

    VAS is the commonly used graphic tool for self-reporting of pruritus intensity in patients. VAS is a simple to use, validated, reliable and widely applicable tool that does not determine the impact of pruritus to quality of life. It comprises of a 100-mm horizontal line labelled as "no symptom" on left end and "worst imaginable symptom" on right end. Based on the intensity of the itch patient is instructed to draw a vertical line on the horizontal scale having a range \[VAS values (unit: mm) ranging from 0 to 100, where 0 represents "no itching" and 100 "worst possible itching"\]. The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  12. Change From Baseline in PBC-40 Quality of Life (QoL) at Week 12 and Week 52

    The PBC-40 QoL questionnaire is a disease-specific health-related tool developed for measuring the psychometric profile in PBC patients. It has 10 domains and 43 questions relevant to PBC, including Cognitive, Social, Emotional Function, Fatigue, Itch, and Other Symptoms. Questions in domains: 1) digestion and diet (questions 1-3); 2) experiences (questions 4-7); 3) itching (questions 8-10); 4) fatigue (questions 11-18); 5) effort and planning (questions 19-21); 6) memory and concentration (questions 22-27); 7) affects to you as person (questions 28-33); 8) affects to your social life (questions 34-37); 9) overall impact on your life (questions 38-40); 10) general health and well-being (questions A-C). Within a domain, items are scored from 1 to 5 and the individual item scores are summed to give a total domain score. High scores represent high impact and low scores low impact of PBC on QoL (mITT Population).

    Time frame: 12 weeks and 52 weeks

  13. Percentage of Participants Meet Published PBC Response Criteria - Barcelona

    Percentage of participants with response based on Barcelona risk scores was defined as Normalization of ALP or a Decrease of ALP ≥ 40%. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  14. Absolute Change in MELD Score From Baseline to 12 Weeks and 52 Weeks

    Change from baseline to 12 weeks and 52 weeks in Model for End-stage Liver Disease (MELD) Score (mITT Population) The MELD score ranges from 6 to 40 and is a measure of how severe a patient's liver disease is. The higher the score, the more likely the patients will need a liver transplant. A calculated prognostic risk factor used to assess the potential need for a liver transplant. MELD(i) score = 10\*\[0.957\*ln(creatinine mg/dL) + 0. 378\*ln(total bilirubin mg/dL) + 1.120\*ln (INR) + 0.643\]. If MELD(i) is less than or equal to 11 then MELD = MELD(i). If MELD(i) is greater than 11 then MELD = MELD(i) + (1.32 \*(137 - (Na)) - (0.033\*MELD(i)\*(137 - Na))

    Time frame: 12 weeks and 52 weeks

  15. Change in GLOBE PBC Score From Baseline to 12 Weeks and 52 Weeks

    Change from Baseline to 12 weeks and 52 weeks in Global PBC Study Group (GLOBE) score (mITT Population) The GLOBE score is a validated risk assessment tool providing an estimate of transplant-free survival for patients with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 patients with PBC. Lower GLOBE score predicts lower risk. It is calculated from the following equation: GLOBE score = (0.044378 \* age + 0.93982 \* LN(total bilirubin/ULN) +(0.335648 \* LN(alkaline phosphatase/ULN)) - 2.266708 \* albumin /LLN -0.002581 \* platelet count per 109/L) + 1.216865

    Time frame: 12 weeks and 52 weeks

  16. Participants Meet Rotterdam Criteria

    participants with Response Based on Rotterdam Criteria at Weeks 12 and 52 Rotterdam Published PBC Response Criteria by Visit (mITT Population) Rotterdam criteria: Early (normal total bilirubin and normal albumin), Moderately advanced (either abnormal albumin or abnormal total bilirubin), and Advanced (both abnormal albumin and abnormal total bilirubin). From Early stage to Moderate Stage and to Advanced Stage, it becomes worse and worse in abnormality.

    Time frame: 12 weeks and 52 weeks

  17. Percentage of Participants Meet Composite Endpoint of AP and Total Bilirubin Criteria at Week 12 and Week 52

    Percentage of participants with Response Defined by Composite Endpoint (ALP\< 1.67 \* Upper Limit of Normal \[ULN\] at Endpoint, Total Bilirubin \[BIL\] within Normal Limits at Endpoint, and Greater Than Equal To \[≥\] 15% ALP Reduction) from Baseline to Week 12 and Week 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

  18. Percent Change in Serum Alkaline Phosphatase (ALP)

    Percent change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

    Time frame: 12 weeks and 52 weeks

07

Results

Posted Jul 14, 2022
Limitations and caveats
First, there was an imbalance in baseline ALP levels among cohorts. Second, the criteria for dose uptitration were not standardized, except that uptitration could only be done at or after Week 12. Third, this was not a placebo-controlled study. Finally, multiplicity adjustments were not made for efficacy endpoints. Nominal p-values were provided for descriptive purposes.

Participant flow

Participant flow — Overall Study
MilestoneMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Started115355
Completed104649
Not completed176
Withdrew: Adverse event030
Withdrew: Withdrawal of informed consent132
Withdrew: Lost to follow-up001
Withdrew: Other013

Outcome measures

PrimaryRelative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8

Relative change from baseline in serum ALP levels at Week 8 (endpoint). The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment. n, denotes number of subjects evaluable for the respective timepoints

Time frame:
8 weeks
Reported as:
Mean · percentage change from baseline
Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8
percentage change from baselineMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Relative Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 8-26.06 ± 9.15-33.38 ± 17.81-41.42 ± 13.05
Statistical analysis
  • MBX-8025 (2 mg) vs MBX-8025 (5 mg) · ANCOVA · p = = 0.2242
  • MBX-8025 (2 mg) vs MBX-8025 (10 mg) · ANCOVA · p = = 0.0021
  • MBX-8025 (5 mg) vs MBX-8025 (10 mg) · ANCOVA · p = = 0.0024
SecondaryAbsolute Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 12 and Week 52

Absolute change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · U/L
Absolute Change From Baseline in Serum Alkaline Phosphatase (ALP) at Week 12 and Week 52
U/LMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Absolute Change at Week 12-68.318 ± 63.276-135.902 ± 150.954-127.867 ± 60.284
Absolute Change at Week 52-101.150 ± 107.956-158.310 ± 143.668-133.760 ± 76.151
SecondaryChange in Aspartate Aminotransferase (AST) From Baseline to 12 Weeks and 52 Weeks

Change from baseline in AST levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · U/L
Change in Aspartate Aminotransferase (AST) From Baseline to 12 Weeks and 52 Weeks
U/LMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 12-2.50 ± 16.72-1.13 ± 24.28-3.35 ± 10.55
Week 52-7.05 ± 10.50-6.18 ± 13.98-6.14 ± 9.18
SecondaryChange in Alanine Aminotransferase (ALT) From Baseline to 12 Weeks and 52 Weeks

Change from baseline in ALT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · U/L
Change in Alanine Aminotransferase (ALT) From Baseline to 12 Weeks and 52 Weeks
U/LMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 12-5.59 ± 16.07-10.48 ± 21.41-10.87 ± 20.25
Week 52-14.30 ± 25.12-17.29 ± 17.46-15.32 ± 13.89
SecondaryChange in Gamma-glutamyl Transferase (GGT) From Baseline to 12 Weeks and 52 Weeks

Change from baseline in GGT levels at endpoint was reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · U/L
Change in Gamma-glutamyl Transferase (GGT) From Baseline to 12 Weeks and 52 Weeks
U/LMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 12-43.68 ± 56.87-75.35 ± 87.57-80.82 ± 109.06
Week 52-78.60 ± 81.59-91.37 ± 102.23-88.08 ± 122.14
SecondaryChange in Bilirubin - Total Bilirubin (TB) From Baseline to 12 Weeks and 52 Weeks

Change from baseline in TB levels at endpoint is being reported. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · mg/dL
Change in Bilirubin - Total Bilirubin (TB) From Baseline to 12 Weeks and 52 Weeks
mg/dLMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 12-0.010 ± 0.121-0.055 ± 0.161-0.067 ± 0.199
Week 520.002 ± 0.152-0.028 ± 0.263-0.068 ± 0.190
SecondaryPercentage of Participants Meet Composite Endpoint Criteria of ALP and Total Bilirubin

Participant meets composite endpoint is defined by participant meets all of the following criteria: * ALP \< 1.67 × upper limit of normal (ULN) * Total Bilirubin within normal limit * \> 15% decrease in ALP Endpoint of Alkaline Phosphatase and Total Bilirubin by Visit (mITT Population)

Time frame:
12 Weeks and 52 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Meet Composite Endpoint Criteria of ALP and Total Bilirubin
percentage of participantsMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 1245.548.966.7
Week 5263.653.367.3
SecondaryPercentage of Participants Meet Published PBC Response Criteria - Paris I

Percentage of participants with response based on Paris I risk score was defined as ALP less than or equal to (≤) 3x ULN and aspartate aminotransferase (AST) less than or equal to (≤) 2 x ULN and Total Bilirubin ≤ 1 mg/dL. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Meet Published PBC Response Criteria - Paris I
percentage of participantsMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 1281.876.175.5
Week 529081.079.2
SecondaryPercentage of Participants Meet Published PBC Response Criteria - Paris II

Percentage of participants with response based on Paris II risk score was defined as ALP≤1.5xULN and AST≤1.5xULN and Total Bilirubin ≤ 1 mg/dL. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Meet Published PBC Response Criteria - Paris II
percentage of participantsMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 1236.437.059.2
Week 5250.054.860.4
SecondaryPercentage of Participants Meet Published PBC Response Criteria - Toronto I

Percentage of participants with response based on Toronto I risk score defined as ALP ≤ 1.67 x ULN. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Number · percentage of subjects
Percentage of Participants Meet Published PBC Response Criteria - Toronto I
percentage of subjectsMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 1263.651.178.4
Week 5263.657.871.4
SecondaryUK-PBC Risk Score Value

The UK-PBC Risk Score at endpoint is defined by the mean percentage risk that a PBC patient treated with ursodeoxycholic acid (UDCA) would develop liver failure requiring liver transplantation in 5, 10 and 15 years from diagnosis. The higher the score might indicate higher risk to death or live transplantation. Formula used for UK-PBC risk score = 1- 0.982 \^EXP(0.0287854\*(ALP12 x ULN-1.722136304) - 0.0422873\*(((TA12 xULN/10)\^-1) - 8.675729006) + 1.4199 \* (LN(BIL12 x ULN/10)+2.709607778)-1.960303\*(Albumin x LLN-1.17673001)-0.4161954\*(Platelet x LLN-1.873564875)). Where, Baseline survivor function = 0.982, 0.941, and 0.893 for 5 years, 10 years and 15 years respectively. ALP12, TA12 and BIL12 refers to the ALP, transaminases (ALT, AST), and total bilirubin assessments, respectively. The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · units on a scale
UK-PBC Risk Score Value
units on a scaleMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
5 years, week 121.3929 ± 0.69762.2553 ± 2.51451.8124 ± 1.7267
5 years, week 521.3145 ± 0.77042.3485 ± 3.4321.7244 ± 1.6121
10 years week 124.5705 ± 2.24797.1229 ± 7.49045.8293 ± 5.3605
10 years, week 524.3128 ± 2.46497.2322 ± 9.57945.5607 ± 5.0092
15 years, week 128.3008 ± 3.993212.4002 ± 12.178510.3469 ± 9.1269
15 years, week 527.8325 ± 4.341312.3028 ± 14.57019.9008 ± 8.5396
SecondaryChange From Baseline in Pruritus Visual Analog Score (VAS) at Week 12 and Week 52

VAS is the commonly used graphic tool for self-reporting of pruritus intensity in patients. VAS is a simple to use, validated, reliable and widely applicable tool that does not determine the impact of pruritus to quality of life. It comprises of a 100-mm horizontal line labelled as "no symptom" on left end and "worst imaginable symptom" on right end. Based on the intensity of the itch patient is instructed to draw a vertical line on the horizontal scale having a range \[VAS values (unit: mm) ranging from 0 to 100, where 0 represents "no itching" and 100 "worst possible itching"\]. The modified Intent-to-Treat (mITT) analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Pruritus Visual Analog Score (VAS) at Week 12 and Week 52
score on a scaleMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 12-3.7 ± 6.4-5.5 ± 25.0-12.3 ± 22.3
Week 52-3.3 ± 11.7-9.6 ± 22.5-16.5 ± 23.0
SecondaryChange From Baseline in PBC-40 Quality of Life (QoL) at Week 12 and Week 52

The PBC-40 QoL questionnaire is a disease-specific health-related tool developed for measuring the psychometric profile in PBC patients. It has 10 domains and 43 questions relevant to PBC, including Cognitive, Social, Emotional Function, Fatigue, Itch, and Other Symptoms. Questions in domains: 1) digestion and diet (questions 1-3); 2) experiences (questions 4-7); 3) itching (questions 8-10); 4) fatigue (questions 11-18); 5) effort and planning (questions 19-21); 6) memory and concentration (questions 22-27); 7) affects to you as person (questions 28-33); 8) affects to your social life (questions 34-37); 9) overall impact on your life (questions 38-40); 10) general health and well-being (questions A-C). Within a domain, items are scored from 1 to 5 and the individual item scores are summed to give a total domain score. High scores represent high impact and low scores low impact of PBC on QoL (mITT Population).

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · units on a scale
Change From Baseline in PBC-40 Quality of Life (QoL) at Week 12 and Week 52
units on a scaleMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
General Symptoms, Week 121.9 ± 2.7-0.7 ± 5.1-0.5 ± 3.6
General Symptoms, Week 520.3 ± 2.4-1.4 ± 4.4-0.1 ± 4.4
Itch, Week 12-0.4 ± 2.0-0.5 ± 3.4-0.8 ± 3.1
Itch, Week 520.4 ± 2.7-1.3 ± 3.2-1.4 ± 3.7
Fatigue, Week 12-1.5 ± 6.1-2.1 ± 10.4-3.0 ± 5.2
Fatigue, Week 52-1.2 ± 7.8-3.0 ± 8.5-3.4 ± 6.3
Cognitive Function, Week 12-0.9 ± 2.4-0.6 ± 5.7-0.7 ± 2.8
Cognitive Function, Week 52-0.7 ± 7.6-1.4 ± 5.3-0.6 ± 2.5
Social, Week 120.8 ± 2.8-0.5 ± 7.9-1.0 ± 6.3
Social, Week 52-3.3 ± 5.2-1.6 ± 7.2-1.6 ± 6.2
Emotional, Week 12-0.9 ± 1.6-1.0 ± 2.6-0.8 ± 2.1
Emotional, Week 52-2.1 ± 2.3-1.3 ± 2.7-0.9 ± 2.1
SecondaryPercentage of Participants Meet Published PBC Response Criteria - Barcelona

Percentage of participants with response based on Barcelona risk scores was defined as Normalization of ALP or a Decrease of ALP ≥ 40%. The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Meet Published PBC Response Criteria - Barcelona
percentage of participantsMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 129.142.662.7
Week 5245.566.765.3
SecondaryAbsolute Change in MELD Score From Baseline to 12 Weeks and 52 Weeks

Change from baseline to 12 weeks and 52 weeks in Model for End-stage Liver Disease (MELD) Score (mITT Population) The MELD score ranges from 6 to 40 and is a measure of how severe a patient's liver disease is. The higher the score, the more likely the patients will need a liver transplant. A calculated prognostic risk factor used to assess the potential need for a liver transplant. MELD(i) score = 10\*\[0.957\*ln(creatinine mg/dL) + 0. 378\*ln(total bilirubin mg/dL) + 1.120\*ln (INR) + 0.643\]. If MELD(i) is less than or equal to 11 then MELD = MELD(i). If MELD(i) is greater than 11 then MELD = MELD(i) + (1.32 \*(137 - (Na)) - (0.033\*MELD(i)\*(137 - Na))

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · Change from Baseline
Absolute Change in MELD Score From Baseline to 12 Weeks and 52 Weeks
Change from BaselineMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 12-0.3 ± 1.60.1 ± 1.20.1 ± 1.0
Week 52-0.7 ± 1.60.3 ± 1.10.2 ± 1.2
SecondaryChange in GLOBE PBC Score From Baseline to 12 Weeks and 52 Weeks

Change from Baseline to 12 weeks and 52 weeks in Global PBC Study Group (GLOBE) score (mITT Population) The GLOBE score is a validated risk assessment tool providing an estimate of transplant-free survival for patients with PBC. It was developed by the Global PBC Study Group using Cox regression model on over 4,000 patients with PBC. Lower GLOBE score predicts lower risk. It is calculated from the following equation: GLOBE score = (0.044378 \* age + 0.93982 \* LN(total bilirubin/ULN) +(0.335648 \* LN(alkaline phosphatase/ULN)) - 2.266708 \* albumin /LLN -0.002581 \* platelet count per 109/L) + 1.216865

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · units on a scale
Change in GLOBE PBC Score From Baseline to 12 Weeks and 52 Weeks
units on a scaleMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 12-0.079 ± 0.260-0.292 ± 0.304-0.346 ± 0.269
Week 52-0.180 ± 0.217-0.271 ± 0.354-0.404 ± 0.298
SecondaryParticipants Meet Rotterdam Criteria

participants with Response Based on Rotterdam Criteria at Weeks 12 and 52 Rotterdam Published PBC Response Criteria by Visit (mITT Population) Rotterdam criteria: Early (normal total bilirubin and normal albumin), Moderately advanced (either abnormal albumin or abnormal total bilirubin), and Advanced (both abnormal albumin and abnormal total bilirubin). From Early stage to Moderate Stage and to Advanced Stage, it becomes worse and worse in abnormality.

Time frame:
12 weeks and 52 weeks
Reported as:
Number · participants
Participants Meet Rotterdam Criteria
participantsMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Early Stage,12 Weeks113840
Early Stage, 52 weeks103642
Moderately advanced at 12 Weeks: Either abnormal Albumin or abnormal Total Bilirubin079
Moderately advanced: 52 Weeks, Either abnormal Albumin or abnormal Total Bilirubin035
Advanced: 12 Weeks, Both abnormal Albumin and abnormal Total Bilirubin010
Advanced: 52 Weeks Both abnormal Albumin and abnormal Total Bilirubin031
SecondaryPercentage of Participants Meet Composite Endpoint of AP and Total Bilirubin Criteria at Week 12 and Week 52

Percentage of participants with Response Defined by Composite Endpoint (ALP\< 1.67 \* Upper Limit of Normal \[ULN\] at Endpoint, Total Bilirubin \[BIL\] within Normal Limits at Endpoint, and Greater Than Equal To \[≥\] 15% ALP Reduction) from Baseline to Week 12 and Week 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Number · percentage of subjects
Percentage of Participants Meet Composite Endpoint of AP and Total Bilirubin Criteria at Week 12 and Week 52
percentage of subjectsMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Week 1245.548.966.7
Week 5263.653.367.3
SecondaryPercent Change in Serum Alkaline Phosphatase (ALP)

Percent change in ALP from baseline to Weeks 12 and 52 The mITT analysis set included all randomized subjects with confirmed PBC who received at least one study drug dose and had at least one post baseline ALP evaluation on treatment.

Time frame:
12 weeks and 52 weeks
Reported as:
Mean · percentage Change
Percent Change in Serum Alkaline Phosphatase (ALP)
percentage ChangeMBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)
Relative Change at Week 12-22.56 ± 13.92-34.49 ± 20.62-43.20 ± 12.39
Relative Change at Week 52-32.72 ± 22.48-40.09 ± 24.23-44.19 ± 15.52

Adverse events

Collected over Up to Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MBX-8025 2 mg0/11 (0%)1/11 (9.1%)11/11 (100%)
MBX-8025 5 mg0/53 (0%)8/53 (15.1%)45/53 (84.9%)
MBX-8025 10 mg0/55 (0%)5/55 (9.1%)47/55 (85.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventMBX-8025 2 mgMBX-8025 5 mgMBX-8025 10 mg
Rib fractureInjury, poisoning and procedural complications1/110/530/55
Febrile neutropeniaBlood and lymphatic system disorders0/111/530/55
Atrial fibrillationCardiac disorders0/111/530/55
Abdominal pain upperGastrointestinal disorders0/111/530/55
PneumoniaInfections and infestations0/111/531/55
Femoral neck fractureInjury, poisoning and procedural complications0/111/530/55
Post procedural haemorrhageInjury, poisoning and procedural complications0/111/530/55
Procedural painInjury, poisoning and procedural complications0/111/530/55
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/111/530/55
SyncopeNervous system disorders0/111/531/55
Most frequent other events
Showing 10 of 75
Most frequent other events
EventMBX-8025 2 mgMBX-8025 5 mgMBX-8025 10 mg
PruritusSkin and subcutaneous tissue disorders6/1111/5312/55
DiarrhoeaGastrointestinal disorders4/117/539/55
NauseaGastrointestinal disorders4/119/536/55
NasopharyngitisInfections and infestations4/115/536/55
Abdominal painGastrointestinal disorders3/113/533/55
Abdominal pain upperGastrointestinal disorders3/117/535/55
DyspepsiaGastrointestinal disorders3/112/531/55
VomitingGastrointestinal disorders3/114/535/55
FatigueGeneral disorders3/119/536/55
Back painMusculoskeletal and connective tissue disorders3/115/533/55

Baseline characteristics

18 to 75 years of age (inclusive)

Age, Categorical
Age, Categorical(Participants)MBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)Total
<=18 years0000
Between 18 and 65 years8414190
>=65 years3121429
Age, Continuous
Age, Continuous(years)MBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)Total
Mean55.2 ± 9.657.5 ± 8.157.4 ± 9.756.4 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)MBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)Total
Female115150112
Male0257
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Subjects)MBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)Total
White105049109
Black or African-American0134
Asian0213
American Indian or Alaska native0011
Other1001
Multiple0011
Region of Enrollment
Region of Enrollment(participants)MBX-8025 (2 mg)MBX-8025 (5 mg)MBX-8025 (10 mg)Total
Canada0516
United States0394382
United Kingdom115420
Germany04711
08

Study locations

38 sites
  • Institute for Liver Health
    Chandler, Arizona 85224, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • Standford University Medicine
    Palo Alto, California 94305, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Ventura Clinical Trials
    Ventura, California 93003, United States
  • Florida Research Institute
    Lakewood Ranch, Florida 34211, United States
  • University of Miami - Center for Liver Diseases
    Miami, Florida 33136, United States
  • Atlanta Gastroenterology Associates, LLC
    Atlanta, Georgia 30308, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Henry Ford Health System
    Novi, Michigan 48377, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Saint Louis University, Gastroenterology & Hepatology
    Saint Louis, Missouri 63104, United States
  • Northwell Health - Center for Liver Disease and Transplantation
    Manhasset, New York 11030, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • The Mount Sinai Medical Center
    New York, New York 10029, United States
  • Northest Clinical Research Center, LLC.
    Bethlehem, Pennsylvania 18017, United States
  • UT Southwestern Medical Center Investigation Drug Service
    Dallas, Texas 75390, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • Gastroenterology Consultants of SA
    Live Oak, Texas 78233, United States
  • Bon Secours St. Mary's Immaculate Hospital
    Newport News, Virginia 23602, United States
  • University of Washington
    Seattle, Washington 98104, United States
  • University of Calgary Liver Unit
    Calgary, Alberta T2N 4Z6, Canada
  • Toronto Centre for Liver Disease
    Toronto, Ontario M5G 2C4, Canada
  • Outpatient Clinic of Internal Medicine
    Berlin, 10117, Germany
  • University Hospital Erlangen
    Erlangen, 91054, Germany
  • Ifi-Studien und Projekte GmbH, An der Asklepios Klinik St. Georg
    Hamburg, 20099, Germany
  • Center of Internal Medicine - Medical School of Hannover
    Hannover, 30625, Germany
  • University Medical Centre of the Johannes Guttenberg-University
    Mainz, 55131, Germany
  • Universitatsklinikum Giessen und Marburg GmbH
    Marburg, 35043, Germany
  • Medizinische Universitatsklinik Tubingen
    Tubingen, 72076, Germany
  • University Hospitals Birmingham
    Birmingham, B15 2GW, United Kingdom
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, CB2 0QQ, United Kingdom
  • Hull and East Yorkshire Hospitals NHS Trust
    Hull, HU3 2JZ, United Kingdom
  • Royal Free London NHS Foundation Trust
    London, NW3 2QR, United Kingdom
  • Plymouth Hospitals NHS Trust
    Plymouth, PL6 8DH, United Kingdom
  • Portsmouth Hospitals NHS Trust
    Portsmouth, PO6 3LY, United Kingdom
09

References and documents

Publications

  • Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, Dorffel Y, Gordon SC, Harrison SA, Kremer AE, Mayo MJ, Thuluvath PJ, Levy C, Swain MG, Neff GW, Sheridan DA, Stanca CM, Berg CP, Goel A, Shiffman ML, Vierling JM, Boudes P, Steinberg A, Choi YJ, McWherter CA. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis. J Hepatol. 2022 Aug;77(2):353-364. doi: 10.1016/j.jhep.2022.02.033. Epub 2022 Mar 30. PubMed 35367282 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Sep 2018, 21 months.

Results were first posted in Jul 2022, 3 years 10 months after primary completion.

Of 21 phase 2 interventional studies under Liver Cirrhosis, Biliary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 21 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2016
First posted
Nov 4, 2016
StartActual
Nov 28, 2016
Primary completionActual
Sep 7, 2018
CompletionActual
Jul 8, 2019
Results first posted
Jul 14, 2022
Last update
Jul 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02955602
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 4, 2016
Start date
Nov 28, 2016
Primary completion
Sep 7, 2018
Completion
Jul 8, 2019
Results posted
Jul 14, 2022
Last update
Jul 14, 2022
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion